Introduction
Infectious diseases are a significant burden on public health. They are responsible worldwide for the largest number of deaths under the age of 44. Knowledge regarding defense mechanisms against infection is therefore of great importance. Susceptibility to infection is determined by multiple factors, which include the virulence and titer of the pathogen, the environment, social factors and resistance of the host. This host resistance is modified by age, immune and nutrition status, stress and, last but not least, by inherited genetic factors.
Genotype can influence the interaction between pathogen and host, and also the immune response of the host. Despite recent progress in the molecular analysis of of cellular immune responses and pathophysiological processes, knowledge as to how all these reactions are controlled at the systemic level is limited. Results obtained from analyzing the response of animals with knock out genes has led to often unexpected results [1] , due to the influence of unknown factors. It is typical for complex diseases that defining mechanisms of disease development is difficult from the analysis of just one controlling gene. This is even more common for complex diseases, which are characterized by multiple controlling genes; therefore, to understand mechanisms of disease development we must know either the majority, or all of the susceptibility genes [2] . The genetic analysis of resistance to infection would therefore help to understand which reaction to an invading pathogen is primary, and which effects are secondary; and how genes interact in regulatory networks. Identification of the most important genes that control infectious disease facilitates the understanding of pathogenesis, and helps to identify therapeutic target [3, 4] . In this review I give examples of genes that control the susceptibility of hosts to infectious diseases. I preferentially concentrate on genes and loci controlling susceptibility with important epidemiologic impact, rather than on rare mutations.
Genes and loci that control susceptibility to human infectious diseases
Some genes and loci, such as those encoding the Major Histocompatibility Antigens (HLA) [5, 6] , mannosebinding lectin/protein (MBP/MBL) [7, 8] , tumor necrosis factor (TNF) [9, 10] , natural resistance associated macrophage protein 1/ solute carrier family 11, member 1 (NRAMP1/SLC11A1) [11] , vitamin D receptor (VDR) [12] and haptoglobin [13] , control susceptibility to a variety of pathogens. Others, such as erythrocyte protein 3 (SLC4A1) [14] , have been described as controlling susceptibility to only a single disease [15] .
Resistance to viruses

HIV
In 2008, the number of people living with HIV (human immunodeficiency virus) was estimated to be 33.4 million, with 2.7 million newly infected individuals, and 2 million deaths from AIDS (AIDS epidemic update, WHO, 2009) . Treatment can slow the progression of disease, but is unable to stop it entirely. However, not everyone who is exposed to HIV becomes infected, as some individuals fail to contract the infection even after repeated exposure to the virus [16] . These people have mutations in genes encoding proteins that control entry of the virus into cells, detection and destruction of the virus by white blood cells, or that inhibit viral replication.
CCR5 and genes for other chemokines
The receptor for chemokines -CCR5 (seven transmembrane spanning chemokine receptor) is a coreceptor for slow-replicating viruses in the early stages of infection [17] . Deletion of 32 base-pairs in its gene leads to the absence of CCR5 protein on the cell surface [18] . This allele is present in Caucasians (8-21%), but is not present in African population, and is found in Asian individuals only very rarely. This mutation in a homozygous state prevents viral entry into white blood cells during the early stages of infection. Prevalence of this mutation in a homozygous state occurs in the population at approximately 1%. Among individuals who have been exposed to infection and are resistant, its frequency increases to 20-30% [19] . Minor effects on resistance to HIV were also observed with mutations in the gene for the chemokine receptor CCR2 (CCR2), and the gene for SDF1 (stromal cellderived factor 1), the principal ligand for CXCR4-type chemokines receptors [20] .
HLA
Differences in the MHC genes may explain a six-fold difference between groups with the shortest and the longest progression times to AIDS [21] . Maximum heterozygosity in the HLA class I loci delayed development of the disease, which was explained by the identification of a larger number of HIV epitopes which were presented to cytotoxic CD8 + lymphocytes. Another mechanism by which MHC genes are involved in resistance to HIV could be via alloantigen response [22] . Analysis of the genes of Kenyan prostitutes that have been exposed to HIV for several years and did not become infected showed that their lymphocytes bear HLA haplotypes that are rare in the local population. It could lead to a strong allogeneic response to HIV infected cells, and to their rapid elimination [22] [23] [24] 25 ].
Haptoglobin
Several independent studies indicate the influence of haptoglobin gene polymorphisms on the replication of HIV, and on the prognosis of disease development. Haptoglobin (Hp) is a protein that binds to haemoglobin and plays a role in oxidative stress induced by iron. It occurs in three major phenotypes: Hp 1-1, Hp 2-1 and Hp 2-2. Distribution in the Caucasian population is approximately 18% Hp 1-1, 50% Hp 2-1, and 32% Hp 2-2. Survival times were on average four years shorter, and the numbers of CD4 + lymphocytes were lower for the Hp 2-2 type, which was associated with higher levels of serum iron, and lower levels of vitamin C, suggesting less effective protection against iron-driven oxidative stress stimulates HIV replication [26] . 
Hepatitis B
Mycobacterium tuberculosis
It is estimated that one third of the world's population is infected by the bacterium Mycobacterium tuberculosis [37] . Infection leads to the development of a wide range of pathologies, from asymptomatic infection to tuberculosis of the lungs and other organs. Annually, tuberculosis accounts for more than three million deaths, and the number of infected individuals continues to increase. The coinfection of HIV and M. tuberculosis is often observed [38, 39] , with mycobacterial infections often proving fatal in immunocompromised hosts [40, 41] . Indeed, tuberculosis is the major cause of death in individuals infected with HIV, and the combination of both illnesses creates unique treatment challenges due to interactions between antituberculous and antiretroviral medications, overlapping drug toxicities, and immune reconstitution inflammatory syndrome [42] .
Evidence for the involvement of genetic factors in tuberculosis was first suggested in 1936 by Diehl and von Versheur in twin studies [43] . These host genetic factors have since been studied extensively using various methods, such as case-controls, candidate gene analysis and genome-wide linkage studies. This latter approach identified a new and important susceptibility locus for infection and diseases on chromosome 18 [44] . Several important candidate genes have been associated with differential susceptibility to TB in various ethnic populations. The most consistent results were obtained with some HLA class II genes, and NRAMP1 (natural resistance associated macrophage protein I) / SLC11A1 (solute carrier family 11 member 1) [12, 45] . Other genes shown to be involved in this process were the vitamin D receptor [46] , SP110, the human homologue of the mouse gene Iprl (intracellular pathogen resistance 1) [47] , genes for cytokines and their receptors [48] , chemokines and their receptors, pattern recognition receptors (including toll-like receptors, mannose binding lectin and the dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin), and purinergic P2X7 receptor gene polymorphisms [49] . The overall effect described for these genes on susceptibility to disease is weak, and it is clear that susceptibility is also affected by other, as yet undiscovered loci. Importantly, it has been demonstrated that tuberculosis in children and adults are two genetically distinct diseases [45] .
Mycobacterium leprae
The earliest case of leprosy was found in the Tomb of the Shroud in Akeldama, Jerusalem, Israel in a burial dating to the first century B.C. The buried male also appeared to have suffered with tuberculosis [50] . Leprosy has been associated for centuries with social stigma, which was partly based on the observation that the disease occurs with a higher frequency in certain families. Several genes and genetic loci that influence susceptibility to M. leprae have been identified. HLA weakly influences the form of disease (tuberculosis or lepromatosis) [51] . Polymorphisms in genes TNFA [52] , TLR2 (Toll-like receptor 2) [53] , TLR4 (Toll-like receptor 4) [54] , NRAMP1/SLC11A1 [55] , VDR (vitamin D receptor) [56] were described to modify the development of disease in some populations. Loci on chromosome 10p13 [57] and 20p12 [58] influence susceptibility to leprosy in India, while locus 6q25-q26 apears to do so in Vietnam [59] . Association analysis also revealed a locus on chromosome 6 was important for susceptibility in Vietnamese and Brazilian patients, as well as the genes PARK2 (parkin) and PARCRG (parkin co-regulated gene) in the genetic cluster associated with ubiquitination and degradation of proteins in proteasomes [60] . A two-stage, genome-wide association study observed a significant association between SNPs in the genes CCDC122, C13orf31, NOD2, TNFSF15, HLA-DR, and RIPK2 and disease development [61] .
Resistance to parasites
Plasmodium ssp.
The four human malaria species of parasitic protozoa are Plasmodium vivax, P. malariae, P. falciparum and P. ovale. The most common is a disease caused by P. falciparum and by P. vivax, which is widespread in tropical and subtropical areas and is manifested as fever, stiffness, headache, myalgia, and anorexia. In 2000, an estimated 350 million to 500 million cases of malaria occurred worldwide and more than 1 million people died from the disease. Despite progress in controlling malaria, the number of death remains very high. According to the WHO (World Health Organisation), there were about 243 million cases of clinical malaria and 863,000 deaths in 2008. Most of the deaths occurred among children less than 5 years of age living in sub-Saharan Africa (Hall B.F., Fauci A.S., Statement on World Malaria Day, April 25 2010, http://www.niaid. nih.gov/news/newsreleases/2010/Pages/malariaday10. aspx). Parasites are becoming increasingly resistant to the drugs used to treat this disease, and an effective vaccination to prevent infection does not currently exist. Because the parasite selection pressure is very strong, different mutations that protect its carrier against disease have expanded during evolution in vulnerable populations. The relationship between thalassemia and sickle cell anemia, caused by different mutations in the haemoglobin molecule, and resistance to malaria, has been known for more than half a century. Further evidence of the influence of genetic factors was obtained from a study of the differences in susceptibility of ethnic groups. Specifically, the Fulani tribe is much less prone to disease than other ethnic groups inhabiting Burkina Faso in West Africa. These genetic differences are not caused by a mutation in haemoglobin or in the HLA genes, but by as yet unknown loci; with IL-4 being a possible candidate [62] .
The first paper demonstrating genetically controled innate resistance to human infectious disease was published in 1954 [63] . To date more than ten different genes controlling resistance have been identified [5, 64] , many of which were discovered by case-control studies. These include the genes for globin [65] , glucose-6-phosphate dehydrogenase [66] , pyruvate kinase [67] , erythrocyte protein 3 (SLC4A1) [14] , genes for the system of blood groups ABO (glycophorin A, glycophorin B) [68] , glycophorin C [69] , chemokine receptor Duffy [70] , CD36 [71] , ICAM1 (intercellular adhesion molecule 1 / CD54) [72] , HLA Class I [51] , HLA Class II [51] , TNF [73] , and genes FCGR2A (CD32 -low-affinity receptor for IgG Fc fragment) [74] , IFNGRI (interferon gamma receptor 1) [75] , IL12B (β chain of the interleukin 12) [76] and NOS2A (inducible nitric oxide synthase) [77] (see Table 1 ). Some of these will be discussed in more detail because they illustrate mechanisms the body uses to resist infection.
Non-immunological mechanisms of protection
Spectrin
Spectrin is the major constituent protein of the erythrocyte cytoskeleton, which forms a filamentous network on the cytoplasmic face of the membrane by providing a scaffold for a variety of proteins [78] . Epidemiological and molecular studies in West Africa have confirmed the prevalence (between 0.6 and 1.6%) of particular spectrin mutations related to hereditary elliptocytosis.
These studies have also revealed the frequency of alphaspectrin chain polymorphisms, associated in cis with elliptocytogenic spectrin mutations, and defining particular spectrin allele haplotypes. In vitro studies of Plasmodium falciparum in elliptocytes bearing such elliptocytogenic variants Spa I/65 or Spa I/46 of spectrin showed that these defects in hereditary elliptocytosis impair the erythrocytic parasite cycles, and are supplementary genetic factors of malaria resistance [79] .
Haemoglobin
Haemoglobin is a transporter for O 2 and CO 2 in red blood cells. In healthy adults the globin molecule consists of two a and two b chains. The a chain is encoded by a gene on chromosome 16, while the b chain is encoded by a gene on chromosome 11. Various mutations in the globin gene in its homozygous state predispose to, or cause, anemia; yet heterozygotes are protected against malaria. Variant of haemoglobin S (HbS), the sickle cell anemia agent b that is produced by substitution of valine for glutamic acid in the globin chain (Glu6Val), is widespread in tropical Africa [80] . People possessing this mutation are protected up to 90% against anemia and cerebral malaria caused by P. falciparum. The Dogon tribe living in Mali carries HbS instead HbC (haemoglobin C; Glu6Lys). This protective effect against P. falciparum is also provided by haemoglobin E (G1u26Lys), whose presence gives rise to a weak b-thalassemia. a-and b-thalassemia occurs in South-East Asia and around the Mediterranean Sea [81] . There is a large number of mutations (more than 120) leading to b-thalassemia, a complex disease associated with hemolytic anemia. The parasitic protozoan Plasmodium is the main selective factor that maintains these mutations in these populations [82] . Mechanisms by which mutations in globin genes protect the host from P. falciparum have only been partially clarified. It appears that cells containing haemoglobin S are more actively removed from the spleens infected with the parasite, and that invasion and parasite growth is more difficult.
Glucose-6-phosphate dehydrogenase (G6PD)
Mature red blood cells have no mitochondria and associated oxidative metabolism, so they depend on the anaerobic metabolism of glucose. An important enzyme for maintaining a reducing environment in red blood cells is glucose-6-phosphate dehydrogenase (G6PD). Deficiency of G6PD is linked to the X chromosome, and heterozygous women and hemizygous men have a reduced incidence of malaria by about half [83] .
Pyruvate kinase (PK)
The human PK-LR gene encodes for erythrocyte PK, which catalyses the conversion of phosphoenolate to pyruvate. This is an essential step in glycolysis and the production of ATP in red blood cells [67] . Mice deficient in PK are protected against malaria [84] , and the growth of P. falciparum in cultures of erythrocytes from humans deficient in PK is retarded [67, 85] . Hence PK deficiency is likely to be one of the factors subject to malarial selection; however, because the mutation is infrequent, its total protective effect in the population is likely to be small.
Erythrocyte protein 3 (Band 3 protein, SLC4A1, CD233)
Gene SLC4A1 is located at locus 17q21-q22, and encodes a protein that is part of the membrane of red blood cells which functions in the exchange of chloride and bicarbonate anions. Mutation (deletion of 27 base pairs), which occurs frequently in Melanesia, is lethal in the homozygous state, but in the heterozygous state it protects against P. falciparum and P. vivax. This mutation does not occur in Africa, likewise the haemoglobin S mutation does not exist in Melanesia [86] .
Blood group antigens: Glycophorins and Duffy antigen
Glycophorins
Antigens of different blood groups are determined by sialoprotein glycophorins A, B and C. P. falciparum may use this membrane protein as one its receptors for cell invasion. Deficiency in glycophorins A and B (blood group 0) has therefore a weak protective effect against P. falciparum [68] , while glycophorin C protects against P. falciparum [69].
Duffy antigen (DARC receptor for chemokines)
DARC on the surface of red blood cells are used by parasite as a receptor. Many people in sub-Saharan Africa carry mutations leading to a lack of expression of the Duffy antigen/receptor, which protects against P. vivax [87] . However, in some human populations P. vivax has been observed in persons lacking DARC. Hence DARC is not the only receptor for P. vivax, but is likely to be a major one for human transmission [88] . It appears that while this mutation confers an advantage for defense against the parasite, it also causes a disadvantage in that it leads to greater susceptibility to prostate cancer [70] .
CD36
One of the critical steps in infection is the adhesion of P. falciparum infected red blood cells to the endothelium of capillaries. Protein CD36 is a major endothelial receptor for red blood cells infected with P. falciparum, and is also expressed on monocytes and platelets. Few mutations that lead to deficiency of the protein have been described, with the most common one being T122646, which constitutes 80% of mutations in this gene. It occurs mainly in people of African descent, and in Caucasian populations has been described only rarely. It is associated with the occurrence of severe cerebral malaria. It cannot, therefore, be explained exactly how selection pressure maintains this mutation in 7.5-18.5% of Africans. It is believed that it may perhaps protect against other, as yet unidentified, infections [71] .
Immunological mechanisms 4.1 HLA Class I
The presence of allele HLA-B53 leads to about a 40% reduction in severe forms of malaria. This allele occurs more widely in Africa, and is rare in other areas. It is interesting that distribution of this allele is similar to distribution of haemoglobin S in the population. HLA recognizes epitope liver forms of the parasite, leading to the induction of cytotoxic T lymphocytes [89] .
HLA Class II
HLA-DR13 haplotype 1 * 1302-DQB 1 * 0501 protect against severe anemia and is common in Gambia [90] .
Schistosoma ssp.
Hepatointestinal schistosomiasis is caused by two species of helminths: Schistosoma japonicum, which is prevalent in Asia, and S. mansoni, which is prevalent in Africa and South America. Both worms develop in the host mesenteric system and lay eggs, triggering inflammation in the hepatic periportal space in which they are trapped. Worms live for years, and thus, chronic liver inflammation and significant tissue destruction are common in infected subjects [91] . A study of Brazilian families, in which the entire genome was scanned for 246 markers, led to the detection of 5q31-q33 on chromosome 5, which controls the number of parasites in the bodies of patients [92] . In this segment there are several potential candidate genes: IL4, IL9, IL13, CSF1, which are known to be involved in the immune response against this fluke. This locus on chromosome 5 also controls the response to S. mansoni in families from Kenya [93] . Other controlling loci are 1p21 and 6p21-q23 -q21 [94] . Within chromosomal segment 6q23 are located additional candidate genes IFNGRI (receptor for interferon g) and CTGF (connective tissue growth factor). It was found that variants in CTGF are associated with hepatic fibrosis in Chinese, Sudanese and Brazilian populations infected with schistosomes [91] . Two Dogon villages where the related pathogen Schistosoma haematobium is endemic were also studied, identifying chromosomal locus 5q31-q33 in a family-based study. Polymorphisms in the candidate gene IL13 were found to be associated with an increased risk of infection [95] . Polymorphisms in STAT6 (12q14) were also associated with infection levels in this population [96] .
Leishmania ssp.
Leishmaniasis is caused by protozoan parasites from the genus Leishmania. They infect mononuclear phagocytes (neutrophils, monocytes and macrophages), as well as dendritic cells and fibroblasts. Parasites are transmitted by phlebotomine sand flies. Several hundred million people in 88 tropical and subtropical countries are at risk for the disease, with two million new cases of leishmaniasis reported annually. Parasites infect mainly macrophages, where they multiply. Infected phagocytes then circulate in the peripheral blood and can infect other cells. In many cases they invade other organs, such as lymph nodes, bone marrow, lungs, spleen or liver. The Leishmania species, along with the genotype and nutrional status of the host, lead to different types of pathology. Indeed patients infected by some species have different symptoms, and can differ in their response to therapy [3] , which appears to be a genetic phenomenon, as several genes may be involved in this process. Genetic control to Leishmania ssp. infection was first described in mice [97, 98] , with later studies identifying multiple genes that control susceptibility to leishmaniasis. Genes coding HLA class I and class II are highly polymorphic, and were revealed to influence the susceptibility to L. (Viannia) guyanensis [99] and L. (V.) brasiliensis [100, 101] . Similar studies did not confirm or demonstrate influence of HLA class II and III polymorphism on susceptibility to visceral disease caused by L. chagasi [102] , L. infantum [103] and L. donovani [104] . Other immune-system genes were tested in candidate-gene studies, and an influence on disease was proven. Specifically, polymorphisms of the IFNγ receptor and IL-4 gene influenced L. donovani post-Kala-azar dermal leishmaniasis [105] . Natural resistance-associated macrophage protein-1 (NRAMP1) has been shown to contribute to an increased risk for visceral leishmaniasis. A further genome-wide association study also identified two loci, 2q23-q24 and 22q12. The gene for IL-2 receptor β (IL2RB) on chromosome 22q12 was studied, and polymorphisms in Sudanese populations may have a functional effect in visceral type of leishmaniasis caused by L. donovani, L. infantum and L. archibaldi. Candidategene association studies in Sudanese tribes identified several polymorphisms in the genes SLC11A1, IL4 and IFNG linked to susceptibility of visceral leishmaniasis. A Brazilian, family-based, genome-wide analysis of people infected by L. donovani identified a locus on chromosome 17 with two chemokine genes CCL1 and CCL16 linked to increased susceptibility [106] .
Integration of human and mouse genetics
Despite remarkable progress in the identification of genes controlling susceptibility to infectious diseases in humans, the complete elucidation of the underlying genetics is hindered by many factors, including sample size, the genetic heterogeneity of human populations, gene interactions, low frequency and/ or incomplete penentrance of trait-controlling alleles and a high variability of environmental factors [107] . Some limitations of human genetic studies can be overcome by the use of mouse models. The availability of genetically homogenous mouse strains, and the ability to test large numbers of F 2 and backcrossed mice in a controlled environment that reduces the phenotypic variance, makes mice a useful model for the study of complex human traits [3] . Once genetic regions of interest have been identified in mice, the high level of synteny between many mouse and human chromosomal segments allows for the prediction of their locations in humans [108] . There are more than 100 mouse models of human diseases, where the homologous genes are mutated in both mice and in humans. In addition, gene expression analysis has demonstrated that conserved coexpression, even with human and mouse phylogenetic distance, represents a very strong criterion to predict disease-relevant relationships among human genes [109] . Using mouse models a number of genes have been identified as being important in human infectious diseases susceptibility, such as NRAMP1 (natural resistance-associated macrophage protein I), SLC11A1 (solute carrier family 11 member 1) [65] or SP110, the human homologue of the mouse gene Ipr1 (intracellular pathogen resistance 1) [110] .
Mouse models of infectious diseases uncover novel components and mechanisms of host response
Using the example of leishmaniasis, it is clear that research using mouse models has generated valuable discoveries for our understanding of biological mechanisms of disease susceptibility. The most extensive information about the genetics of leishmaniasis in mouse models has been obtained with Leishmania major. These genetic studies have used several model systems, which include comparisons of two or more inbred strains [111] [112] [113] , congenic strains [114, 115] , recombinant inbred strains [115] and recombinant congenic strains [116] [117] [118] [119] [120] . Genetic studies, especially those using recombinant congenic strains, led to a dissociation of correlated phenotypes, and showed that disease or healing in different strains occurs in association with different components of the immune response [121] . This research also revealed a multigenic basis of susceptibility by mapping of more than 20 quantitative trait loci (QTLs) -Lmr -Leishmania major response loci ( Table 2 ). The functional effects of individual QTLs differ widely, indicating networked regulation of these effects (Table 2) . Studies using mouse models have revealed functional heterogeneity of individual susceptibility genes, and indicate organ specific control of the antiparasite response [117, 119, 120] . Moreover, parasite elimination, as well as immunological and pathological processes, are under independent regulation [118] . A combination of recombinant mapping in combination with advanced tools of system genetics led to the identification of a potential candidate gene Fli1 (Friend leukemia integration 1) for Lmr2 [122] , which uncovered a novel mechanism in the control of leishmaniasis. These findings together indicate that susceptibility to L. major is not due to a single mechanism, but rather can result from several different combinations of effects from multiple genes that interact in a functional network. It is interesting that for the majority of Leishmania susceptibility loci identified in mice, syntenic chromosomal segments control leishmaniasis in humans [106] , indicating the validity of using mice to model human disease. Lmr loci might also be relevant for analysis of other diseases, as was shown by detection of the position homologous to mouse Lmr9 on the human chromosome 8q12 novel atopy controlling locus [123] .
In the recent years, emerging, innovative geneticstrategies, such as somatic genetics, modifier screens and humanized mice, in combination with whole-genome mutagenesis and tools of systems biology, have dramatically broaden the utility of the mouse. This will further enable researchers to gain an understanding of the molecular mechanisms and pathways underlying health, as well as those responsible for pathogenesis.
Conclusion
Rapid advances in the knowledge of human and mouse genome sequences, together with emerging innovative genetic strategies, provide knowledge of mapped chromosomal segments, leading to the identification of candidate genes. At the same time, the development of new techniques promises affordable and rapid typing of a large number of loci, which allows the characterization of individual patients. This will lead to a better definition of the genetic heterogeneity of disease, better assesment of the prognosis of disease development, and, in many cases, will help to optimize treatment.
